$ADPT Income Statement | Understand Stock

$ADPT

$26.27 +$0.76 (2.98%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Sequencing Revenue
Development Revenue
Total revenue

Operating expenses
Cost of revenue
Research and development
Sales and marketing
General and administrative
Amortization of intangible assets
Impairment of right-of-use and related long-lived assets
Impairment of long-lived assets
Total operating expenses
Loss from operations
Interest and other income, net
Interest expense
Net loss
Add: Net (income) loss attributable to noncontrolling interest
Net loss attributable to Adaptive Biotechnologies Corporation
Net loss attributable to Adaptive Biotechnologies Corporation common shareholders
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted

Comments